NCT02927353View on ClinicalTrials.gov

A Phase 1 Pharmacokinetic Bioequivalence Study of DMB-3113 and Adalimumab in Healthy Japanese Adult Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

January 17, 2017

Study Completion Date

January 17, 2017

Conditions
Healthy Volunteer
Interventions
DRUG

DMB-3113

subcutaneously injected in a single dose of 40 mg.

DRUG

Adalimumab

subcutaneously injected in a single dose of 40 mg.

Trial Locations (1)

Unknown

Fukuoka

Sponsors
All Listed Sponsors
lead

Meiji Seika Pharma Co., Ltd.

INDUSTRY